DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Cure Ventures Management, LP
Cure Ventures Management, LP
Standard of Cure Embracing Evidence. Increasing Success. Saving Lives. How We Go All-In With Entrepreneurs, We Bring Cures to Life Learn More Our People Moving Medicine Forward Dr. Michael Aberman XenImmune Leveraging the robust immune response to target tumors like never before. Read Michael’s Story Dr. Milenko Cicmil Tasca Therapeutics Unlocking post-translational modification to expand […]
venture manager, reported GAV $322M across 1 vehicles
Importance
26
moderate
Active deployment
0
low
Emerging
0
low
Completeness
63
high
Freshness
100
high
Research priority
5
low
Identity and regulatory footprint
- Headquarters
- Boston, MAadviserinfo.sec.gov
- Office address
- 349-351 NEWBURY STREET, Boston, MA, 02115adviserinfo.sec.gov
- Business phone
- 617-319-3254adviserinfo.sec.gov
- Website
- https://www.curevc.com/
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 11, 2026
- Private funds reported
- 2 (2 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $690Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Cure Ventures Management, LLC (General Partner), NA
- business email
- info@curevc.comcurevc.compublished by the subject
- business email
- 02115info@curevc.comcurevc.compublished by the subject
- business phone
- 617-319-3254adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
no observed deals yet
Stated (the firm’s website)
- Sectors
- biotech, media
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors: no observed deals yet
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Cure Ventures Fund I, L.P. | Fund | 2021 form d first sale | Mature | $322M Mar 26, 2024 | 44 | $350M of $350M | Apr 4, 2023 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
17 current, 11 departed
Weihan Liu
AssociateAssociate
David R Fallace
Managing partnerManaging Partner · since May 1, 2021
LOU Tartaglia
Managing partnerManaging Partner
LOU Tartaglia
Managing partnerManaging Partner · since May 1, 2021
Richard Jinkyu Lim
Managing partnerManaging Partner · since May 1, 2021
Tasca Therapeutics
OtherOur Portfolio is Always Growing
Albert J. Robichaud
PartnerPartner
Annie Mitsak
PartnerPartner
Jeffrey M. Jonas
PartnerPartner
Jeno Gyuris
PartnerPartner
Kenzie Maclsaac
PartnerPartner
Kim Szottfried
Platform and operationsExecutive Assistant & Office Manager
Milenko Cicmil
Venture partnerVenture Partner
Kayarash Karimian
Vice presidentSenior Associate
Sophie Robinson
Vice presidentSenior Associate
Virginia Lyle King
Vice presidentSenior Associate
11 departed (kept with end dates)
- Weihan Liu · Associate · ? to Sep 16, 2026 Inference
- Lou Tartaglia · Managing Partner · ? to Sep 16, 2026 Inference
- Albert J. Robichaud · Partner · ? to Sep 16, 2026 Inference
- Annie Mitsak · Partner · ? to Sep 16, 2026 Inference
- Jeno Gyuris · Partner · ? to Sep 16, 2026 Inference
- Kenzie Maclsaac · Partner · ? to Sep 16, 2026 Inference
- May Han · Partner · ? to Sep 16, 2026 Inference
- Milenko Cicmil · Venture Partner · ? to Sep 16, 2026 Inference
- Kayarash Karimian · Senior Associate · ? to Sep 16, 2026 Inference
- Sophie Robinson · Senior Associate · ? to Sep 16, 2026 Inference
- Virginia Lyle King · Senior Associate · ? to Sep 16, 2026 Inference
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
13 dated events
- Sep 16, 2026Lou Tartaglia (Managing Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceLou TartagliaVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Sophie Robinson (Senior Associate) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceSophie RobinsonVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Albert J. Robichaud (Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceAlbert J. RobichaudVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Annie Mitsak (Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceAnnie MitsakVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Kenzie Maclsaac (Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceKenzie MaclsaacVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Weihan Liu (Associate) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceWeihan LiuVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Virginia Lyle King (Senior Associate) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceVirginia Lyle KingVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Kayarash Karimian (Senior Associate) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceKayarash KarimianVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026May Han (Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceMay HanVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Jeno Gyuris (Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceJeno GyurisVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Milenko Cicmil (Venture Partner) no longer on the team page of Cure Ventures Management, LPPerson leftPeopleInferenceMilenko CicmilVenture organization websites (about, team, portfolio, thesis, news pages)
- Jul 22, 2021Cure Ventures Fund I, L.P. first reported on Form ADV by Cure Ventures Management, LP (Venture Capital Fund)Fund first reported on Form ADVFundsFactCure Ventures Fund I, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jul 22, 2021Cure Ventures Management, LP first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $322M across 1 vehicles
Evidence
45 observations from 3 sources